![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ADRX-0706 is an ADC comprised of a novel fully human IgG1 antibody targeting human Nectin-4, being investigated for the treatment of select advanced solid tumors.
Lead Product(s): ADRX-0706
Therapeutic Area: Oncology Product Name: ADRX-0706
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Details:
Under the terms of the collaboration, Adcentrx will specify targets against which AvantGen will screen for novel antibodies using yeast display system. Adcentrx will be responsible for engineering the antibodies into ADC therapeutic candidates and has commercialization rights.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: AvantGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 14, 2022
Details:
Series A financing is raised to power the development of next generation ADC for improving patient treatment options.
Lead Product(s): Antibody drug conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: CBC Group
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 28, 2021